Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4B | P0C869 | 6/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | RARB | P10826 | 5/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6132822 | 0.95 | TP53 (0.75) | PLA2G4BTSHRTP53PKMMAPK1 | |
| SCHEMBL6132656 | 0.95 | TP53 (0.75) | PLA2G4BTSHRTP53PKMMAPK1 | |
| SCHEMBL18682480 | 0.95 | TP53 (0.75) | PLA2G4BTSHRTP53PKMMAPK1 | |
| SCHEMBL8747416 | 0.91 | RARB (0.74) | PLA2G4BTSHRTP53PKMMAPK1 | |
| SCHEMBL2741522 | 0.91 | PKM (0.72) | PLA2G4BTSHRTP53PKMMAPK1 | |
| SCHEMBL118037 | 0.90 | PKM (0.77) | PLA2G4BTSHRTP53PKMMAPK1 | |
| SCHEMBL7329413 | 0.90 | RARB (0.77) | PLA2G4BTSHRTP53PKMRARB | |
| SCHEMBL18682414 | 0.90 | RARB (0.77) | PLA2G4BTSHRTP53PKMRARB | |
| SCHEMBL21260346 | 0.90 | RARB (0.68) | PLA2G4BTSHRTP53PKMMAPK1 | |
| SCHEMBL7332700 | 0.90 | RARB (0.77) | PLA2G4BTSHRTP53PKMRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210032532-A1 | PHOTOCHROMIC COMPOUND, CURABLE COMPOSITION CONTAINING SAID PHOTOCHROMIC COMPOUND, AND OPTICAL ARTICLE | TOKUYAMA CORPORATION (JP) | 2021-02-04 | — | — | US | disclosed |
| US-8586609-B2 | Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-11-19 | — | — | US | disclosed |
| US-20100298378-A1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-11-25 | — | — | US | disclosed |
| US-7838547-B2 | Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| US-20070299077-A1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299077-A1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | PAH, NAT1, AADAT | PLA2G4B 3480/4885TSHR 995/4885TP53 2932/4885 |
| US-20100298378-A1 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | PAH, NAT1, AADAT | PLA2G4B 3480/4885TSHR 995/4885TP53 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.